| |
The scientific community universally recognizes peer-reviewed literature as the foundation of credible and reproducible research. However, its exponential growth presents a significant challenge for R&D teams in biotech and pharma companies. Learn how to leverage AI to ensure that today’s advancements in drug discovery, clinical trials and regulatory processes are based on data that is up-to-date, validated and meaningful. Download now.
|
|
Today’s Big NewsJul 14, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| By Conor Hale For 2025, the to-be-combined company’s portfolios and its 16,000 total employees are expected to generate about $6.5 billion in sales. |
|
|
|
By Angus Liu The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new FDA leadership’s much-touted support for cell and gene therapies against rare diseases. |
By Gabrielle Masson International companies are increasingly inking licensing deals with China biotechs as concerns regarding drug pricing and patent expirations continue to rise. |
By Kevin Dunleavy The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure. Now, another drug class has reached the market that could further alter the HF landscape. The FDA has expanded the label of Bayer’s Kerendia, a nonsteroidal selective mineralocorticoid receptor antagonist, to include treatment of patients with two types of heart failure. |
|
Wednesday, July 23, 2025 | 2pm ET / 11am PT The development of radiopharmaceuticals is transforming oncology. Designing successful clinical trials in this space, requires a precise balance of insight, efficiency, and strategy. Join our expert panel to explore the imaging strategies, trial design principles, and regulatory alignment considerations you need to know about. Register now.
|
|
By Darren Incorvaia Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. The New Jersey pharma is teaming up with the Gates Foundation to launch a pair of phase 3 trials of its once-monthly, oral pre-exposure prophylaxis (PrEP) prospect. |
By Zoey Becker Sun will pay Incyte royalties on its Leqselvi in exchange for a license on certain patents at the heart of Incyte's lawsuit that previously blocked the JAK inhibitor's U.S. launch. |
By James Waldron AstraZeneca’s $1.3 billion bet CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based on a phase 3 readout. |
By Zoey Becker With the WNBA All-Star Game set to take place this weekend in Indianapolis, hometown pharma Lilly is taking the opportunity to bring breast cancer awareness back to the court with a weekend of early detection-centered activities. |
By Kevin Dunleavy Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis. The site played a major role in Bristol's $4.1 billion acquisition of RayzeBio in December 2023. |
By James Waldron Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R)-selective agonist scored a pair of phase 3 wins. |
By Andrea Park It may not be an Olympic year, but Humana is still firing up some competition this summer. |
By Kevin Dunleavy For the second time this year, dermatology specialist Leo Pharma has struck a partnership with a major drugmaker, paying Boehringer Ingelheim 90 million euros ($105 million) up front to develop and commercialize Spevigo, a drug approved in 2022 to treat a rare skin disease. . |
Fierce podcastsDon’t miss an episode |
| Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend. |
|
|---|
|
|
|
QPS delivers global RWE solutions to support regulatory and drug development goals. With access to diverse data sources and deep regulatory expertise, QPS transforms real-world data into actionable insights.
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| |
|
